Journal of Clinical Oncology · 2009 · 1K citations · 38 references
MedicineOncologyPharmacologyBreast OncologyCancer PharmacologyMolecular OncologyBreast Cancer PharmacotherapyHer2-positive Breast CancerHormonal TherapyMenopause PharmacotherapyMetastatic Breast CancerTyrosine Kinase InhibitorsEndocrine ResistanceHer2-positive Metastatic DiseaseHormone Receptor - Positive Breast CancerHormone Receptor Positive Metastatic DiseaseHormone Receptor-positive Breast Cancer TherapyLetrozole TherapyMetastatic Breast Cancer TreatmentTyrosine Kinase Inhibitor Therapy
Cross‑talk between EGFR/HER2 and hormone receptors can drive endocrine resistance in breast cancer. The study assessed whether adding lapatinib to letrozole improves first‑line therapy for postmenopausal women with hormone‑receptor‑positive metastatic breast cancer. Patients were randomized to receive letrozole plus lapatinib or letrozole plus placebo, with progression‑free survival as the primary endpoint in HER2‑positive cases. In HER2‑positive metastatic breast cancer, lapatinib plus letrozole significantly extended progression‑free survival (median 8.2 vs 3.0 months, HR 0.71) and increased clinical benefit (48 % vs 29 %), whereas no benefit was seen in HER2‑negative disease; higher but manageable grade 3/4 toxicity occurred.
Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), to the aromatase inhibitor letrozole as first-line treatment of hormone receptor (HR) -positive metastatic breast cancer (MBC).Postmenopausal women with HR-positive MBC were randomly assigned to daily letrozole (2.5 mg orally) plus lapatinib (1,500 mg orally) or letrozole and placebo. The primary end point was progression-free survival (PFS) in the HER2-positive population. Results In HR-positive, HER2-positive patients (n = 219), addition of lapatinib to letrozole significantly reduced the risk of disease progression versus letrozole-placebo (hazard ratio [HR] = 0.71; 95% CI, 0.53 to 0.96; P = .019); median PFS was 8.2 v 3.0 months, respectively. Clinical benefit (responsive or stable disease >or= 6 months) was significantly greater for lapatinib-letrozole versus letrozole-placebo (48% v 29%, respectively; odds ratio [OR] = 0.4; 95% CI, 0.2 to 0.8; P = .003). Patients with centrally confirmed HR-positive, HER2-negative tumors (n = 952) had no improvement in PFS. A preplanned Cox regression analysis identified prior antiestrogen therapy as a significant factor in the HER2-negative population; a nonsignificant trend toward prolonged PFS for lapatinib-letrozole was seen in patients who experienced relapse less than 6 months since prior tamoxifen discontinuation (HR = 0.78; 95% CI, 0.57 to 1.07; P = .117). Grade 3 or 4 adverse events were more common in the lapatinib-letrozole arm versus letrozole-placebo arm (diarrhea, 10% v 1%; rash, 1% v 0%, respectively), but they were manageable.This trial demonstrated that a combined targeted strategy with letrozole and lapatinib significantly enhances PFS and clinical benefit rates in patients with MBC that coexpresses HR and HER2.
38
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Michel Marty, Francesco Cognetti, D Maraninchi et al. · IRIS UNIMORE (University of Modena and Reggio Emilia) · 2005 · 1.6K citations · Full text
Medicine, Oncology, Pharmacology +17